Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Show more

Location: 2265 Upper Middle Road East, Oakville, ON, L6H 0G5, Canada | Website: https://www.cardiolrx.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

111.3M

52 Wk Range

$0.77 - $2.24

Previous Close

$1.17

Open

$1.17

Volume

463,335

Day Range

$1.12 - $1.17

Enterprise Value

74.14M

Cash

18.2M

Avg Qtr Burn

-6.267M

Insider Ownership

3.79%

Institutional Own.

9.20%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.